Registered as an emerging drug development company, Rock Creek Pharmaceuticals engages in the development and commercialization of novelty medications that are geared towards addressing the needs in neurologic disorders and inflammatory diseases.
The company is based in Sarasota, Florida. It conducts its research and development on its own and through partnership with other pharmaceutical companies. The lead product of the company is the compound Anatabine Citrate, which is a small molecule cholinergic agonist. This compound has strong anti-inflammatory characteristics that are completely different from steroids, non-steroidal anti-inflammatories and biologics. Studies of this compound in the United Kingdom have already commenced to check its safety and tolerability in health subjects.
Other than the inflammatory products being developed by the company, the business is also into the development of smoking cessation pharmaceuticals. Rock Creek Pharmaceuticals, Inc. publicly trades its common shares on the NASDAQ using the ticker symbol RCPI.
No comments:
Post a Comment